Intelligent Bio Solutions Inc (INBS) Stock Analysis
Verdict: AVOID
Clinical progress is undercut by a $12.05M annual cash burn and chronic dilution, making INBS a high-risk binary play on FDA approval.
Investment score: 23/100
Analysis as of
Is Intelligent Bio Solutions Inc stock worth reviewing? AI model thesis
From the model's perspective, INBS is an uninvestable micro-cap for core portfolios due to an annual free cash flow burn of -$12.05M against a cash balance of just $3.99M as of June 2026. While FDA 510(k) trial accuracy above 98% offers a potential clinical catalyst, the model notes that continuous dilutive financing—including the September 2026 $5M private placement—destroys long-term shareholder equity value.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Intelligent Bio Solutions Inc opportunities and risks
What speaks for INBS
- Planned FDA 510(k) submission in September 2026 backed by clinical accuracy exceeding 98.2%.
What speaks against INBS
- Chronic structural cash burn of -$12.05M FCF in FY2026 against a cash balance of $3.99M.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INBS | n/a | 0.3x | 0.1x | 27.7% | -294.9% | -847.5% |
| SCND | n/a | 1.7x | n/a | 29.2% | -13.0% | -69.2% |
| NDRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -102.1% |
| CODX | n/a | 1.8x | 0.0x | 8.1% | -6523.0% | -2121.5% |
| NVNO | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -7745.4% |
| CYDX | n/a | 98.9x | n/a | 60.7% | -532.2% | 0.2% |
| Peer median | n/a | 1.7x | n/a | 8.1% | -13.0% | -102.1% |
Frequently asked questions about Intelligent Bio Solutions Inc (INBS)
Is INBS stock a good investment?
The cached TradeMates AI model rates Intelligent Bio Solutions Inc as AVOID with an investment score of 23/100. From the model's perspective, INBS is an uninvestable micro-cap for core portfolios due to an annual free cash flow burn of -$12.05M against a cash balance of just $3.99M as of June 2026. While FDA 510(k) trial accuracy above 98% offers a potential clinical catalyst, the model notes that continuous dilutive financing—including the September 2026 $5M private placement—destroys long-term shareholder equity value. This is algorithmic model output, not personal investment advice.
Is INBS stock a buy?
The TradeMates model verdict for INBS is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.